Literature DB >> 16157365

Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.

Christopher M Lee1, Dennis C Shrieve, Karen A Zempolich, R Jeffrey Lee, Elizabeth Hammond, Diana L Handrahan, David K Gaffney.   

Abstract

OBJECTIVE: To investigate prognostic significance of and correlations between HER1 (EGFR), HER2 (c-erb-B2), HER3 (c-erb-B3), HER4 (c-erb-B4), and phosphorylated Akt (P-Akt) in patients treated with radiation for cervical carcinoma.
METHODS: Fifty-five patients with stages I-IVA cervical carcinoma were treated with definitive radiotherapy. Tumor expression of each biomarker was quantitatively scored by an automated immunohistochemical imaging system. Parametric correlations were performed between biomarkers. Univariate and multivariate analysis was performed with disease-free survival (DFS) and overall survival (OS) as primary endpoints.
RESULTS: Correlations were observed between expression of HER2 and HER4 (P = 0.003), and HER3 and HER4 (P = 0.004). Decreased HER2, HER4, and P-Akt expressions were significant for diminished DFS on univariate analysis (P = 0.04, P = 0.008, and P = 0.02, respectively). Increased EGFR, and diminished HER2, HER4, and P-Akt expression were significant or showed trends toward significance for diminished OS on univariate analysis (P = 0.07, P = 0.008, P = 0.09, and P = 0.08, respectively). After controlling for pretreatment factors, multivariate analysis revealed HER2 associated with improved OS (P = 0.05).
CONCLUSIONS: These data emphasize that significant correlations exist between the differential expression of various HER family receptors. Multivariate analysis revealed only increased HER2 expression associated with improved OS after controlling for pretreatment clinical factors. These data emphasize the importance of continued basic and translational research on the HER family of receptors in cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157365     DOI: 10.1016/j.ygyno.2005.05.045

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  33 in total

Review 1.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

Review 2.  Chemoradiotherapy for cervical cancer in 2010.

Authors:  Ann H Klopp; Patricia J Eifel
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

Review 3.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

4.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Authors:  Christopher P Mill; Michael D Zordan; S Michael Rothenberg; Jeffrey Settleman; James F Leary; David J Riese
Journal:  Genes Cancer       Date:  2011-08

5.  Caveolin-1 is involved in radiation-induced ERBB2 nuclear transport in breast cancer cells.

Authors:  Yu Zhang; Shiying Yu; Liang Zhuang; Zu'an Zheng; Tengfei Chao; Qiang Fu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

6.  Association between ErbB3 genetic polymorphisms and coronary artery disease in the Han and Uyghur populations of China.

Authors:  Buamina Maitusong; Xiang Xie; Yi-Tong Ma; Zhen-Yan Fu; Yi-Ning Yang; Xiao-Mei Li; Fen Liu; Bang-Dang Chen; Min-Tao Gai
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 7.  Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

8.  Induction of ERBB2 nuclear transport after radiation in breast cancer cells.

Authors:  Bo Luo; Shiying Yu; Liang Zhuang; Shu Xia; Zhen Zhao; Lei Rong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

Review 9.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

10.  Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86.

Authors:  C Beskow; J Skikuniene; A Holgersson; B Nilsson; R Lewensohn; L Kanter; K Viktorsson
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.